Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Gibco™ Human Flt-3 Ligand (FLT3L) Recombinant Protein, PeproTech®

Click to view available options
Quantity:
1 mg
10 μg
100 μg
2 μg
250 μg
50 μg
500 μg
Description
Recombinant Human Flt3-Ligand is a soluble 17.6 kDa protein consisting of 155 amino acid residues. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
FLT3LG (Fms Related Tyrosine Kinase 3 Ligand) is a Protein Coding gene. Diseases associated with FLT3LG include Aplastic Anemia and Brain Cancer. Among its related pathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Ras signaling pathway. Gene Ontology (GO) annotations related to this gene include protein homodimerization activity and cytokine activity. Dendritic cells (DCs) provide the key link between innate and adaptive immunity by recognizing pathogens and priming pathogen-specific immune responses. FLT3LG controls the development of DCs and is particularly important for plasmacytoid DCs and CD8-positive classical DCs and their CD103-positive tissue counterparts.

Specifications
Specifications
Accession Number | P49771 |
For Use With (Application) | ELISA, Functional Assay, Western Blot |
Formulation | protein with no preservative |
Gene ID (Entrez) | 2323 |
Molecular Weight (g/mol) | 17.6 kDa |
Name | Human Flt-3 Ligand (FLT3L) |
Quantity | 100 μg |
Source | E. coli |
Regulatory Status | RUO |
Endotoxin Concentration | <1 EU/ μg |
Show More |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction